HER2 status-Positive Page 2 Posts on Medivizor
Navigation Menu

HER2 status-Positive Posts on Medivizor

Can pertuzumab improve long-term response rates in HER2-positive breast cancer?

Posted by on Mar 14, 2016 in Breast cancer | 0 comments

In a nutshell The authors aimed to assess whether adding pertuzumab (Perjeta) to chemotherapy could improve response in women with metastatic (has spread) breast cancer. This study showed that adding pertuzumab to chemotherapy resulted in higher response rates among women with breast cancer that relied on the human epidermal growth factor 2 (HER2) to...

Read More

Combining targeted therapies: the benefits of directly targeting HER2+ breast cancer

Posted by on Oct 10, 2015 in Breast cancer | 0 comments

In a nutshell The authors aimed to determine the effectiveness of targeted treatments and also compared combination therapies. Some background HER2 positive breast cancer is associated with the over-expression (production) of the human epidermal growth factor receptor 2 (HER2+). HER2+ breast cancer is known to be more aggressive with a poorer...

Read More

Retargeting: Treatment for metastatic HER2+ breast cancer that has progressed following targeted treatment

Posted by on Jul 18, 2015 in Breast cancer | 0 comments

In a nutshell The authors reviewed the benefits and safety of ado–trastuzumab emtansine (Kadcyla), a treatment for metastatic breast cancer (cancer that has spread to other areas of the body). Some background Human epidermal growth factor receptor 2 positive (HER2) breast cancer depends on HER2 for growth. Treatments that target the HER2...

Read More

Breast cancer in elderly women; can trastuzumab treatment increase the risk of heart failure?

Posted by on Jun 24, 2015 in Breast cancer | 0 comments

In a nutshell The authors aimed to determine the risks of developing cardiac or heart problems while being treated with trastuzumab (Herceptin) for breast cancer. Some background Trastuzumab is a form of endocrine or hormone therapy used to treat patients with human epidermal growth factor 2 positive (HER2+) breast cancer. Since the approval of...

Read More

Is there any need for trastuzumab after surgery if you received trastuzumab before surgery?

Posted by on Apr 28, 2015 in Breast cancer | 0 comments

In a nutshell This paper studied the effect of adjuvant therapy (treatment given after surgery) in patients who had a complete response to therapy with trastuzumab (Herceptin) before surgery.  Some background Neoadjuvant systemic therapy is treatment used to decrease the size of the tumour before surgery. An example of treatment...

Read More

What is the role of HER2 in ductal carcinoma in situ?

Posted by on Mar 30, 2015 in Breast cancer | 0 comments

In a nutshell This paper studied the role of human epidermal growth factor receptor 2 (HER2, protein receptor)  in ductal carcinoma in situ. Some background Ductal carcinoma in situ refers to cancer that starts growing from the milk ducts but has not spread to surrounding breast tissue.  Treatment of ductal carcinoma in situ usually...

Read More

Does T-DM1 have a different impact on symptoms in breast cancer compared to alternative treatment?

Posted by on Dec 11, 2014 in Breast cancer | 0 comments

In a nutshell This study evaluated the benefit of the new HER2-targeted therapy T-DM1 compared to an often-used alternative treatment. Some background Breast cancers expressing the human epidermal growth factor receptor 2 protein are known as HER2-positive cancer. In recent years therapies that directly target the HER2 protein, for...

Read More

A review of pertuzumab and its use in HER2 blockade

Posted by on Aug 23, 2013 in Breast cancer | 0 comments

In a nutshell This article reviewed data from recent clinical trials investigating the drug pertuzumab (perjeta) as treatment for metastatic HER2+ breast cancer. Some background HER2 (human epidermal growth factor receptor 2) is a protein found on the surface of some cancer cells. This complex responds to molecules called growth factors, and...

Read More

Trastuzumab emtansine as treatment for advanced HER2 positive breast cancer

Posted by on Jul 10, 2013 in Breast cancer | 1 comment

In a nutshell This trial compared treatment with trastuzumab (herceptin) in combination with docetaxel, to a new combination drug called trastuzumab emtansine. Some background Some breast cancer cells have certain receptors on their surface that respond to growth inducing molecules. These cancers are referred to as being human epidermal growth...

Read More